January 30, 2012 8:30 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that it has submitteda request to the European Medicines Agency (EMA) for a re-examination of thenegative opinion issued in January by the EMA's Committee For MedicinalProducts for Human Use (CHMP) for conditional approval of FOLOTYN^ for the treatment of patients with peripheral T-celllymphoma whose disease has progressed after at least one prior systemictherapy. PTCL comprises a biologically diverse group of aggressive, rare bloodcancers that have a worse prognosis than most other types of lymphoma,including B-cell lymphoma. According to current CHMP guidelines, a finalopinion on the re-examination could be issued by the EMA within four to fivemonths.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.